Browse by Nurse Practitioner Items

Nurse practitioner PBS prescribing

MEDICINES WHICH MAY BE PRESCRIBED BY AUTHORISED NURSE PRACTITIONERS

From 1 September 2010, nurse practitioners endorsed to prescribe under state or territory legislation can apply for approval as PBS prescribers (authorised nurse practitioners) Information for nurse practitioners to become authorised PBS prescribers is available from the Department of Human Services.

The medicines listed for prescribing by authorised nurse practitioners from 1 November 2010 are identified by ‘NP’ in the PBS Schedule. Nurse practitioners must not write PBS prescriptions for other medicines.

PBS prescribing is limited by a nurse practitioner’s scope of practice, and state and territory prescribing rights. Prescribing of PBS medicines is also contingent on a prescriber being an authorised nurse practitioner and having collaborative arrangements in place, as required by amendments to the National Health Act 1953.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations to the Minister for Health regarding medicines for prescribing by authorised nurse practitioners.

Further to prescribing within collaborative arrangements, certain medicines also have additional conditions for prescribing by nurse practitioners, as recommended by the PBAC. These medicines are identified by the codes ‘CTO’ for continuation therapy only or ‘SCM’ for prescribing within a shared care model, as outlined below:

  • Continuing therapy only model

Where the patient’s treatment and prescribing of a medicine has been initiated by a medical practitioner, but prescribing is continued by a nurse practitioner. (This is similar to existing arrangements between specialists and medical practitioners for prescribing certain medicines.)

  • Shared care model

Where care is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed plan to manage the patient, in a patientcentred model of care. The details surrounding shared care arrangements will depend on the practitioners involved, patient needs and the healthcare context.

Some medicines are included in more than one section of the Schedule, and for more than one prescriber type. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their prescriber type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Nurse practitioner PBS prescriptions are identifiable by colour, and include the indicator ‘NP’ on personalised forms and a tick box on non-personalised (blank) forms.

Prescriptions must include the nurse practitioner’s PBS prescriber number. For unrestricted and restricted PBS medicines, midwives/nurse practitioners can use the personalised or non-personalised PBS prescriber forms.  For authority required and authority required (streamlined) PBS medicines, midwives/nurse practitioners can use the authority personalised or non-personalised PBS prescriber forms.  Nurse practitioner PBS prescriptions may include repeats. 

Regulation 49 applies for nurse practitioner prescribing. A nurse practitioner can direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time, if certain conditions are satisfied.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from the Department of Human Services for each prescription. (Refer to Prescribing Medicines — Information for PBS prescribers and Supplying medicines — What Pharmacists Need to Know, for more information on authority prescriptions.)

State and territory requirements: Nurse practitioners may prescribe medicines as private prescriptions according to their state/territory prescribing accreditation. The medicines which can be prescribed differ between states and territories. It is the nurse practitioner’s responsibility to ensure adherence to State/Territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS prescriptions.

  • Legend
  • MPMedical Practitioner
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MPNP 8559L GABAPENTINgabapentin 600 mg tablet, 100 1 100 5
MPNP 8505P GABAPENTINgabapentin 100 mg capsule, 100 1 100 5
MPNP 1835N GABAPENTINgabapentin 400 mg capsule, 100 1 100 5
MPNP 8389M GABAPENTINgabapentin 800 mg tablet, 100 1 100 5
MPNP 1834M GABAPENTINgabapentin 300 mg capsule, 100 1 100 5
MPNP 2537M GALANTAMINEgalantamine 16 mg modified release capsule, 28 1 28 5
MPNP 8771P GALANTAMINEgalantamine 16 mg modified release capsule, 28 1 28 5
MPNP 2531F GALANTAMINEgalantamine 24 mg modified release capsule, 28 1 28 5
MPNP 8772Q GALANTAMINEgalantamine 24 mg modified release capsule, 28 1 28 5
MPNP 2463P GALANTAMINEgalantamine 8 mg modified release capsule, 28 1 28 5
MPNP 8770N GALANTAMINEgalantamine 8 mg modified release capsule, 28 1 28 5
MPNP 1453L GEMFIBROZILgemfibrozil 600 mg tablet, 60 1 60 5
MPNP 2824P GENTAMICINgentamicin 80 mg/2 mL injection, 10 x 2 mL ampoules 1 10 1
MPNP 11344C GLECAPREVIR + PIBRENTASVIRglecaprevir 100 mg + pibrentasvir 40 mg film-coated tablet, 84 1 84 3
MPNP 11353M GLECAPREVIR + PIBRENTASVIRglecaprevir 100 mg + pibrentasvir 40 mg film-coated tablet, 84 1 84 1
MPNP 11354N GLECAPREVIR + PIBRENTASVIRglecaprevir 100 mg + pibrentasvir 40 mg film-coated tablet, 84 1 84 2
MPNP 2939Q GLIBENCLAMIDEglibenclamide 5 mg tablet, 100 1 100 5
MPNP 9302N GLICLAZIDEgliclazide 60 mg modified release tablet, 60 1 60 5
MPNP 2449X GLICLAZIDEgliclazide 80 mg tablet, 100 1 100 5
MPNP 8535F GLICLAZIDEgliclazide 30 mg modified release tablet, 100 1 100 5
MPNP 8533D GLIMEPIRIDEglimepiride 3 mg tablet, 30 1 30 5
MPNP 8451T GLIMEPIRIDEglimepiride 2 mg tablet, 30 1 30 5
MPNP 8452W GLIMEPIRIDEglimepiride 4 mg tablet, 30 1 30 5
MPNP 8450R GLIMEPIRIDEglimepiride 1 mg tablet, 30 1 30 5
MPNP 2440K GLIPIZIDEglipizide 5 mg tablet, 100 1 100 5
MPNP 1449G GLUCAGON HYDROCHLORIDEglucagon hydrochloride 1 mg injection [1 vial] (&) inert substance diluent [1 mL syringe], 1 pack 1 1 1
MPNP 3467L GLUCAGON HYDROCHLORIDEglucagon hydrochloride 1 mg injection [1 vial] (&) inert substance diluent [1 mL syringe], 1 pack 1 1 0
MPNP 3107M GLUCOSE AND KETONE INDICATOR URINEglucose and ketone indicator urine diagnostic strip, 50 2 2 2
MPNP 3104J GLUCOSE INDICATOR URINEglucose indicator urine diagnostic strip, 50 2 2 2
MPNP 1459T GLYCERYL TRINITRATEglyceryl trinitrate 600 microgram sublingual tablet, 100 1 1 5
MPNP 1515R GLYCERYL TRINITRATEglyceryl trinitrate 5 mg/24 hours patch, 30 1 30 5
MPNP 8010N GLYCERYL TRINITRATEglyceryl trinitrate 5 mg/24 hours patch, 30 1 30 5
MPNP 8027L GLYCERYL TRINITRATEglyceryl trinitrate 5 mg/24 hours patch, 30 1 30 5
MPNP 11027J GLYCERYL TRINITRATEglyceryl trinitrate 300 microgram sublingual tablet, 100 1 1 5
MPNP 3475X GLYCERYL TRINITRATEglyceryl trinitrate 400 microgram/actuation oral spray, 200 actuations 1 1 0
MPNP 8171C GLYCERYL TRINITRATEglyceryl trinitrate 400 microgram/actuation oral spray, 200 actuations 1 1 5
MPNP 1516T GLYCERYL TRINITRATEglyceryl trinitrate 10 mg/24 hours patch, 30 1 30 5
MPNP 8011P GLYCERYL TRINITRATEglyceryl trinitrate 10 mg/24 hours patch, 30 1 30 5
MPNP 8028M GLYCERYL TRINITRATEglyceryl trinitrate 10 mg/24 hours patch, 30 1 30 5
MPNP 8026K GLYCERYL TRINITRATEglyceryl trinitrate 15 mg/24 hours patch, 30 1 30 5
MPNP 8119H GLYCERYL TRINITRATEglyceryl trinitrate 15 mg/24 hours patch, 30 1 30 5
MPNP 10195N GLYCINE WITH CARBOHYDRATEglycine with carbohydrate containing 500 mg of glycine oral liquid: powder for, 30 x 4 g sachets 4 4 5
MPNP 2644E GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals bar, 7 x 81 g 14 14 5
MPNP 10528D GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals containing 15 g of protein equivalent oral liquid, 30 x 250 mL cartons 4 4 5
MPNP 10359F GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals containing 10 g of protein equivalent oral liquid, 30 x 250 mL cartons 4 4 5
MPNP 11279P GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals containing 20 g of protein equivalent powder for oral liquid, 30 x 32 g sachets 4 4 5
MPNP 11084J GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals powder for oral liquid, 60 x 20 g sachets 5 5 5
MPNP 10992M GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals powder for oral liquid, 30 x 51 g sachets 4 4 5
MPNP 10652P GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals powder for oral liquid, 30 x 49 g sachets 4 4 5
MPNP 2696X GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals bar, 7 x 54 g 14 14 5
MPNP 11290F GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals containing 15 g of protein equivalent bar, 14 x 81 g 8 8 5
MPNP 11287C GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals containing 10 g of protein equivalent powder for oral liquid, 60 x 16 g sachets 2 2 5
MPNP 10332T GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALSglycomacropeptide and essential amino acids with vitamins and minerals containing 15 g protein oral liquid, 30 x 250 mL cartons 4 4 5
MPNP 11071Q GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINEglycomacropeptide formula with docosahexaenoic acid and low phenylalanine powder for oral liquid, 30 x 35 g sachets 4 4 5
MPNP 11245W GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINEglycomacropeptide formula with docosahexaenoic acid and low phenylalanine powder for oral liquid, 30 x 27 g sachets 4 4 5
MPNP 10059K GLYCOPYRRONIUMglycopyrronium 50 microgram powder for inhalation, 30 capsules 1 30 5
MPNP 8873B GRANISETRONgranisetron 2 mg tablet, 5 1 5 1
MPNP 8728J GRANISETRONgranisetron 2 mg tablet, 1 2 2 0
MPNP 8729K GRANISETRONgranisetron 3 mg/3 mL injection, 3 mL ampoule 1 1 0
MPNP 8730L GRANISETRONgranisetron 3 mg/3 mL injection, 3 mL ampoule 1 1 0
MPNP 2982Y GRISEOFULVINgriseofulvin 500 mg tablet, 28 1 28 2
MPNP 1460W GRISEOFULVINgriseofulvin 125 mg tablet, 100 1 100 2